Swedish biotechnology company Active Biotech AB (STO:ACTI) on Tuesday announced positive results from a clinical phase I study of laquinimod eye drops in patients undergoing vitrectomy.

The ongoing biodistribution study has demonstrated that laquinimod can penetrate the cornea and sclera to reach the anterior and posterior chambers of the eye.

These findings support the potential of laquinimod as a treatment for ocular disorders, such as uveitis. The company plans to continue the study to evaluate the safety and efficacy of laquinimod eye drops in patients with uveitis.